TG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of $2.43, $2.21 better than the analyst estimate of $0.22. Revenue for the quarter came in at $161.7 million versus the consensus estimate of $152.23 million.

2025 Financial Guidance

Raises BRIUMVI U.S. net product revenue target to approximately $585 million for the full year 2025 (prior guidance of $570 - $575 million for full year 2025)
Raises total global revenue target to approximately $600 million for the full year 2025 (prior guidance of $585 million for full year 2025)

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.